Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Improving Live Birth Rates in Women Under 37 with Infertility Using cpFT During ICSI

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying infertility and aims to improve the chances of having a live baby after a procedure called Intracytoplasmic Sperm Injection (ICSI). The treatment being tested is a solution called cpFT, which contains an active substance known as cpFT trifluoroacetate. This solution is not given directly to patients but is added to the culture medium used in the laboratory to help with the development of eggs and embryos before they are transferred to the woman’s uterus.

The purpose of the study is to see if using cpFT can increase the rate of live births in women under 37 years of age who are undergoing their first embryo transfer. During the study, participants will undergo the standard ICSI procedure, but with the addition of cpFT to the culture medium. The study will last for a maximum of six days, during which the development of the eggs and embryos will be closely monitored. The study will compare the outcomes of those who receive the cpFT treatment with those who do not, to determine if there is a significant improvement in live birth rates.

Participants in the study will not receive the cpFT solution directly, as it is only used in the laboratory setting. The study will also look at various factors related to embryo development, such as the number of mature eggs, the quality of embryos, and the rate of successful pregnancies. The ultimate goal is to find a way to help more couples achieve a successful pregnancy and have a healthy baby through the use of this innovative treatment.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria. Participants include couples requiring medically assisted reproduction, eligible for ICSI, with women aged 18 to 36 and men aged 18 to 58. Participants must use a specific culture medium and be affiliated with a social security system.

  2. Step 2

    Preparation for treatment

    The study involves the use of a solution called cpFT. This solution is used to supplement the medium in which oocytes and preimplantation embryos are incubated before the first embryo transfer. The concentration of cpFT used is 1 micromolar (1µM).

  3. Step 3

    Embryo transfer

    The primary goal is to improve the rate of live births after the first embryo transfer. The process involves monitoring the development of embryos and assessing their quality before transfer.

  4. Step 4

    Monitoring and follow-up

    After the embryo transfer, several factors are monitored, including the number of oocytes collected, embryo development, and quality. The study also tracks pregnancy progress, including the presence of cardiac activity at 12 weeks, and any pregnancy-related complications.

  5. Step 5

    Birth and postnatal follow-up

    The study continues to monitor outcomes at birth, including the baby's weight, height, and head circumference. Pediatric consultations are conducted until the child is one year old to assess development using specific scales.

Who can join the trial?

6 criteria

  • Couples who need Medically Assisted Reproduction (help from doctors to have a baby).
  • Couples who are eligible for ICSI (a special procedure where a single sperm is injected directly into an egg to help with fertilization).
  • Women who are between 18 and 36 years old.
  • Men who are between 18 and 58 years old.
  • Use of CSCM-C culture medium from Biocare/Irvine, exclusively (a specific type of solution used in the lab to support the growth of embryos).
  • People who are part of a Social Security system (a government program that provides financial support and healthcare).

Who cannot join the trial?

4 criteria

  • Participants must be **women under 37 years of age**.
  • Participants must be experiencing **infertility**.
  • Participants must be eligible for a procedure called **ICSI** (Intracytoplasmic Sperm Injection), which is a type of fertility treatment.
  • Participants must not belong to a **vulnerable population**, which means they should not be in a group that needs special protection in research, like children or people with certain disabilities.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

cpFT is a special supplement used in this clinical trial to help improve the chances of having a live baby after a procedure called ICSI, which is a type of fertility treatment. In this study, cpFT is added to the liquid that surrounds the eggs before the ICSI procedure and also to the liquid that surrounds the embryos before they are placed into the womb. The goal is to see if using cpFT can help more women under the age of 37 have successful pregnancies and healthy babies.

What is already known about the treatment

cpFT – cpFT is administered as a supplement to the incubation medium used in the process of in vitro fertilization, specifically during the pre-ICSI (Intracytoplasmic Sperm Injection) incubation of oocytes and preimplantation embryos. Currently, cpFT is being studied in clinical trials to assess its effectiveness in improving live birth rates in women under 37 years of age undergoing ICSI. The main therapeutic indication for cpFT is infertility, as it aims to enhance the success rates of assisted reproductive technologies. At the molecular level, cpFT is believed to support embryo development, although the exact mechanism of action is still under investigation. It is classified pharmacologically as a fertility treatment supplement.

Investigated diseases

Infertility – Infertility is a condition where an individual is unable to conceive after a year of regular, unprotected sexual intercourse. It can affect both men and women and may result from various factors, including hormonal imbalances, structural issues, or problems with sperm or egg production. In women, infertility may be due to ovulation disorders, blocked fallopian tubes, or uterine abnormalities. In men, it often involves low sperm count, poor sperm motility, or abnormal sperm shape. The condition can be temporary or permanent, depending on the underlying cause. Infertility can lead to emotional and psychological stress for those affected.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-514350-78-00Protocol codeP170706JEstimated enrolment366 patientsSponsorAssistance Publique Hopitaux De Paris

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).